Wake Forest WF-1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Objective

This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.

https://clinicaltrials.gov/ct2/show/NCT03475186

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Studies

Specialty

• Brain Cancer

Contact

Cancer Clinical Trials at 218-786-3308
or cancertrials@essentiahealth.org